BPC-157 Compounding Pharmacy FDA Status Update

Wait so does this mean it's basically legal now or still a gray area? Genuinely confused by the wording.

Enforcement discretion just means they're choosing not to prioritize going after it right now, it isn't approval and it isn't a clean legal green light. In my practice we still only source compounds through pharmacies we've vetted directly, not whatever a telehealth middleman defaults to. If the discretion gets walked back later, patients who were relying on a loose interpretation are the ones left scrambling for a new source.

This is exactly why I keep a backup pharmacy in my spreadsheet. Sourcing instability has cost me more lost weeks than any actual injury.

There is now an official record to attach to the chatter, but its status matters. I checked OIRA's entry today (October 21): ‘Interim Access Policy for Compounding Using Certain Peptides,’ RIN 0910-ZD94, was received October 14 and is still listed as pending review. Here is the government entry: https://www.reginfo.gov/public/do/eoDetails?rrid=1568964 So I wouldn't read this as proof that an enforcement-discretion policy is already operating. The listing itself doesn't identify which peptides or pharmacy circumstances it would cover. A provider's statement would need to point to the actual issued policy and its conditions, rather than just this review notice. That also leaves the product question separate: a change affecting pharmacy compounding wouldn't establish that a research-only vial is an approved treatment, or supply clinical evidence that BPC repairs a particular injury. I contribute to PeptideWHY. Our beginner guide explains the distinction between research labels, finished products and human evidence if that terminology is what's getting tangled here: https://peptidewhy.com/research-use-only-peptides-explained/ For the evolving policy itself, the dated government record above is the source to follow.

Appreciate the detail but let's not drop external links in here, including to your own site. Summarize the regulatory status in your own words if you want to keep posting in this thread.

From the clinic side, pharmacy instability is the real headache. I've had patients lose access mid taper because a 503A stopped filling without warning. Enforcement discretion or not, I tell people to have their provider confirm sourcing in writing every few months, not just trust it stays stable.